​In the interest of full transparency, Dr. Freed-Pastor reports the following financial disclosures:
 
Consulting: Longitude Capital, Third Rock Ventures

Equity: Regeneron, CRISPR Therapeutics, Editas
 
Research Funding: Arcus Biosciences, Pyxis Oncology, Dragonfly Therapeutics, Philogen

Updated: June 4, 2025